Cell Therapy Manufacturing Market Outlook (2023 to 2033)

The global cell therapy manufacturing market size is expected to reach a valuation of US$ 4,134.48 million in 2023 and further expand at a CAGR of 14.2% from 2023 to 2033. The market is anticipated to reach a valuation of ~US$ 15,634.67 million by the end of 2033. Autologous cell therapy manufacturing is leading the global market and held a share of about 56.0% in 2021.

A sophisticated gene-edited cell-based product such as chimeric antigen receptor (CAR)-T cells or tissue engineering products like Holoclar are examples of modern cell therapies that include but are not limited to blood transfusion and hematopoietic progenitor stem cell transplantation exclusively. Quality standards have evolved in response to the continual improvement of cell therapy manufacturing processes, thereby resulting in improved product consistency, reliability, and efficacy.

Manufacturing processes need a transition from open and manual to closed and automated in order to scale up. This offers several benefits such as decreased risk of contamination, improved product uniformity, increased efficiency, and surging traceability throughout the process to assure the chain of custody.

In order to reduce risks and get ready for a high-production future, groups in both academia and industry are actively implementing novel technologies that help them build automated, scalable, and closed systems. Key players are also working on the development of innovative technologies that assist investigators in automating their processes for success in the future.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Top Trend Pushing Sales in the Global Cell Therapy Manufacturing Industry

  • Rising Practice of Manufacturing Capability Outsourcing

It is challenging and time-consuming for businesses that are not familiar with the cell therapy manufacturing process to build a solid supply chain with the tools and processes required to satisfy consumer demand.

Companies that have a strong understanding of the biology of their product, but are unfamiliar with how to transition from a small, manual production to a scaled-up, automated production that serves the needs of hundreds of thousands of patients globally, quickly bridge the gap with the help of an outside organization, such as a contract manufacturing organization (CMO).

Outsourcing of manufacturing capabilities creates growth opportunities for new industry entrants to scale up their products for wide-scale distribution. Additionally, outsourcing saves manufacturers from making investments in large-scale systems and facilitates anticipation of future product delays or regulatory denials.

Which Factors Are Limiting Demand in the Cell Therapy Manufacturing Industry?

Manufacturers of cell therapies face certain process limitations when they aim to provide a functional and safe output from an extremely variable starting material. Increased starting material variability poses limitations on the production protocols for desired end use products.

Additionally, as different phases in the production of cell therapy require variable timespans, bottlenecks develop in a fully automated system by holding one part of equipment engaged for a longer duration of time, while the rest of the system sits idle, not utilizing resources and wasting both time & space.

The design is more efficient in a modular system as only one part of the system is engaged and the rest of the system is available for usage. Another drawback of fully automated systems is that they could bind an organization or a research team to a certain methodology.

Attributes Details
Cell Therapy Manufacturing Market CAGR (2023 to 2033) 14.2%
Cell Therapy Manufacturing Market Size (2023) US$ 4,134.48 million
Cell Therapy Manufacturing Market Size (2033) US$ 15,634.67 million
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

2018 to 2022 Cell Therapy Manufacturing Demand Outlook Compared to 2023 to 2033 Forecast

The cell therapy manufacturing industry held approximately 3.3% of the global targeted therapeutics market, which was worth ~US$ 3,685.7 million in 2022. The global cell therapy manufacturing market expanded at a CAGR of 10.7% from 2018 to 2022 owing to the positive outcomes of immunotherapy.

In its most precise definition, cell therapy manufacturing starts with the patient's cell collection in a clinical (or apheresis) facility and ends with the patient receiving the finished drug at their bedside. Numerous hand-off points and activities occur between the initial raw material collection and the subsequent administration of a product.

Cell therapy manufacturing differs from more conventional pharmaceutical production due to the complexity of all these working components in a supply chain, as well as the blend of the production and delivery phases. The majority, if not all, cell therapies currently available are only meant to treat a small number of patients.

However, if they are to be made widely accessible for a variety of indications, advancements in automation, process simplification, and supply chain management are necessary to keep up with the rising demand. Owing to the aforementioned factors, the global market is expected to surge at a CAGR of 14.2% during the forecast period.

Comparative View of the Market

Cell Therapy Manufacturing Market:

Attributes Cell Therapy Manufacturing Market
CAGR (2023 to 2033) 14.2%
Market Value (2033) US$ 15,634.67 million
Growth Factor Rising prevalence of sickle cell disease
Opportunity Manufacturers focus on automation
Key Trends Introduction new processing methods

Stem Cell Therapy Market:

Attributes Stem Cell Therapy Market
CAGR (2023 to 2033) 16.7%
Market Value (2033) US$ 1,182.06 million
Growth Factor Expanding research in stem cell
Opportunity Rising demand for innovative medicines
Key Trends

Rise in public-private financing

Cell and Gene Therapy Clinical Trial Market:

Attributes Cell and Gene Therapy Clinical Trial Market
CAGR (2023 to 2033) 27.5%
Market Value (2033) US$ 152,110 million
Growth Factor Surge in cancer cases
Opportunity Explicit gene modification techniques
Key Trends Surged commercialization in cell and gene therapy

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

What Makes the United States a Large Market for Cell Therapy Manufacturing?

The United States dominates the North American region and held a total share of about 42.1% in 2022. The country is expected to continue to remain at the forefront throughout the forecast period. The increasing prevalence of sickle cell disease in the country and the presence of a large number of gene & cell and tissue-based therapeutic developers are likely to drive growth. As per the Centers for Disease Control and Prevention (CDC), sickle cell disease affects nearly 100,000 Americans and it occurs among about 1 out of every 16,300 Hispanic-American births.

What Makes the United Kingdom a Highly Lucrative Market for Cell Therapy Manufacturing?

The United Kingdom held approximately 26.6% of the Europe market in 2022. The country reflects a lucrative outlook toward cell therapy manufacturing. As per the European Medicines Agency, from 2018 until 2020, nearly 102% of advanced therapy classifications occurred across Europe annually.

What is the Outlook of China in the Cell Therapy Manufacturing Market?

China held a share of around 38.2% in 2021 in the East Asia cell therapy manufacturing market, finds FMI. Chinese local biotech businesses are working with industry associations to develop guidelines for maintaining high product quality and introducing new processing methods in an effort to streamline cell therapy manufacturing. China is likely to hold a market CAGR of 22.1% by 2033.

For instance, SALIAI, a leading stem cell start-up, is promoting the establishment of production and quality standards for the stem cell sector while collaborating with the China Quality Association for Pharmaceuticals.

Category-wise Insights

Which is the Highly Preferred Source?

The autologous source segment held the leading share of around 56.0% in 2022. Growth is attributed to various advantages of autologous sources in stem cell transplant. They help in promoting faster recovery of cell counts, reducing mortality rates associated with the treatment modality, and providing a shorter length of hospital stays.

Which is the Leading Indication Segment?

Cancer is expected to showcase high growth at a CAGR of 14.8% by the end of the forecast period. As per FMI, the segment held a market share of about 31.0% in 2022. The high incidence rate of cancer, as well as the growing adoption of novel treatment models for targeted therapy, are propelling the segment in the global cell therapy manufacturing market.

Which is the Dominant Purpose of Cell Therapy Manufacturing?

For pre-clinical, clinical, and commercial scaling of cell therapy products, manufacturing processes promote adoptive standardization for each protocol. Clinical manufacturing held a high market share of around 42.0% in the global market, followed by commercial manufacturing, which accounted for a share of about 32.0% globally in 2022.

Which Route of Administration is Set to Exhibit Lucrative Growth?

Injectables held a market share of about 44.0% in 2022 in the global market. Injectables promote greater absorption of therapeutic drugs at the target site and hence contribute to a positive outcome for disease treatment. Moreover, injections for cell therapy exhibit better cell retention at the targeted site of the disease.

Which is the Most Prominent Cell Type?

The hematopoietic stem cells (HSC) segment held a share of around 25.0% in 2022 in the cell therapy manufacturing market as many malignant disorders, including leukemia and lymphoma, as well as non-malignant conditions such as sickle cell disease, are treated with HSCs in order to replace or rebuild the patient's hematopoietic system.

Which End User Benefits the Most in the Global Market?

Hospital settings held the leading market share of around 38.1% in 2022, says FMI. This segment is emerging as a valuable end user with the advancement of point-of-care manufacturing of cell therapies in units close to hospital settings for increased accessibility of treatment, as well as to reduce treatment time and risk of contamination.

Competitive Landscape

Competitive Landscape

The global cell therapy manufacturing market is fragmented with the presence of a large number of companies. They are striving persistently to build digital capabilities for cell therapy production. These efforts help them to optimize their business processes and expand their portfolios in the global market.

For instance,

  • In April 2022, Lonza added additional integrated capabilities in cell separation, bead removal, and cell binding with the release of its second-generation instrument. It helps in extending the functionality of the company’s Cocoon Platform with magnetic selection capability for cell therapy manufacturing.
  • In April 2022, Catalent acquired Erytech Pharma for its industrial-scale cell therapy production plant in Princeton, New Jersey. The arrangement includes an exclusive long-term supply partnership, thereby enabling Catalent to promote red blood cell-derived therapy, eryaspase (GRASPA) by Erytech for acute lymphoblastic leukemia.

Key players

  • Merck KGaA
  • Avantor, Inc.
  • Cell Therapies Pty Ltd
  • Thermo Fisher Scientific
  • Charles River Laboratories
  • Catalent, Inc
  • Bio-Techne
  • Cytiva
  • Lonza
  • The Discovery Labs
  • BIOCENTRIC
  • FUJIFILM Diosynth Biotechnologies
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • WuXi AppTec.
  • OXGENE
  • Pharmaron
  • Aldevron
  • FLODESIGN SONICS
  • Exothera

Key segments

By Source:

  • Autologous
  • Allogenic

By Indication:

  • HIV
  • Autoimmune Disorders
  • Immune Deficiencies
  • Cancer
  • Neurological Disorders

By Manufacturing Purpose:

  • Clinical
  • Commercial
  • Pre-clinical

By Route of Administration:

  • Topical
  • Injectable
  • Infusion
  • Implantable Bio-Scaffold

By Cell Type:

  • Hematopoietic (Blood-Forming) Stem Cells (HSC)
  • Skeletal Muscle Stem Cells
  • Mesenchymal Stem Cells
  • Lymphocytes
  • Dendritic Cells
  • Pancreatic Islet Cells
  • CAR-T Cells

By End User:

  • Hospital Settings
  • Intensive Outpatient Treatment Centers
  • Academic and Research Institutes
  • Specialty Clinics

By Region :

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

What is the Historical Cell Therapy Manufacturing Market Share?

The cell therapy manufacturing sector expanded at a share of US$ 3,685.79 million in 2022.

Which country is set to register exponential growth in the Cell Therapy Manufacturing market?

The United States is set to register exponential growth in the cell therapy manufacturing market.

What drives sales of cell therapy manufacturing?

The increasing demand for cell therapy products and the growing number of clinical trials are expected to drive cell therapy manufacturing sales.

What key trends are driving the Cell Therapy Manufacturing Market?

The rising adoption of automation and the increasing focus on personalized medicine are key trends driving the cell therapy manufacturing market.

What opportunities await for the Market Players?

Substantial investment in research and development and expansion into new markets are expected to provide growth prospects for the market players.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Source

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Source, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Source, 2023 to 2033

        5.3.1. Autologous

        5.3.2. Allogenic

    5.4. Y-o-Y Growth Trend Analysis By Source, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Source, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        6.3.1. HIV

        6.3.2. Autoimmune Disorders

        6.3.3. Immune Deficiencies

        6.3.4. Cancer

        6.3.5. Neurological Disorders

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Manufacturing Purpose 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Manufacturing Purpose, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Manufacturing Purpose, 2023 to 2033

        7.3.1. Clinical

        7.3.2. Commercial

        7.3.3. Pre-clinical

    7.4. Y-o-Y Growth Trend Analysis By Manufacturing Purpose, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Manufacturing Purpose, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        8.3.1. Topical

        8.3.2. Injectable

        8.3.3. Infusion

        8.3.4. Implantable Bio-Scaffold

    8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cell Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Million) Analysis By Cell Type, 2018 to 2022

    9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cell Type, 2023 to 2033

        9.3.1. Hematopoietic (Blood-Forming) Stem Cells (HSC)

        9.3.2. Skeletal Muscle Stem Cells

        9.3.3. Mesenchymal Stem Cells

        9.3.4. Lymphocytes

        9.3.5. Dendritic Cells

        9.3.6. Pancreatic Islet Cells

        9.3.7. CAR-T Cells

    9.4. Y-o-Y Growth Trend Analysis By Cell Type, 2018 to 2022

    9.5. Absolute $ Opportunity Analysis By Cell Type, 2023 to 2033

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    10.1. Introduction / Key Findings

    10.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        10.3.1. Hospital Settings

        10.3.2. Intensive Outpatient Treatment Centers

        10.3.3. Academic and Research Institutes

        10.3.4. Specialty Clinics

    10.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    10.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    11.1. Introduction

    11.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    11.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Western Europe

        11.3.4. Eastern Europe

        11.3.5. South Asia and Pacific

        11.3.6. East Asia

        11.3.7. Middle East and Africa

    11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. U.S.

            12.2.1.2. Canada

        12.2.2. By Source

        12.2.3. By Indication

        12.2.4. By Manufacturing Purpose

        12.2.5. By Route of Administration

        12.2.6. By Cell Type

        12.2.7. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Source

        12.3.3. By Indication

        12.3.4. By Manufacturing Purpose

        12.3.5. By Route of Administration

        12.3.6. By Cell Type

        12.3.7. By End User

    12.4. Key Takeaways

13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Brazil

            13.2.1.2. Mexico

            13.2.1.3. Rest of Latin America

        13.2.2. By Source

        13.2.3. By Indication

        13.2.4. By Manufacturing Purpose

        13.2.5. By Route of Administration

        13.2.6. By Cell Type

        13.2.7. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Source

        13.3.3. By Indication

        13.3.4. By Manufacturing Purpose

        13.3.5. By Route of Administration

        13.3.6. By Cell Type

        13.3.7. By End User

    13.4. Key Takeaways

14. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Germany

            14.2.1.2. U.K.

            14.2.1.3. France

            14.2.1.4. Spain

            14.2.1.5. Italy

            14.2.1.6. Rest of Western Europe

        14.2.2. By Source

        14.2.3. By Indication

        14.2.4. By Manufacturing Purpose

        14.2.5. By Route of Administration

        14.2.6. By Cell Type

        14.2.7. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Source

        14.3.3. By Indication

        14.3.4. By Manufacturing Purpose

        14.3.5. By Route of Administration

        14.3.6. By Cell Type

        14.3.7. By End User

    14.4. Key Takeaways

15. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Poland

            15.2.1.2. Russia

            15.2.1.3. Czech Republic

            15.2.1.4. Romania

            15.2.1.5. Rest of Eastern Europe

        15.2.2. By Source

        15.2.3. By Indication

        15.2.4. By Manufacturing Purpose

        15.2.5. By Route of Administration

        15.2.6. By Cell Type

        15.2.7. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Source

        15.3.3. By Indication

        15.3.4. By Manufacturing Purpose

        15.3.5. By Route of Administration

        15.3.6. By Cell Type

        15.3.7. By End User

    15.4. Key Takeaways

16. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. India

            16.2.1.2. Bangladesh

            16.2.1.3. Australia

            16.2.1.4. New Zealand

            16.2.1.5. Rest of South Asia and Pacific

        16.2.2. By Source

        16.2.3. By Indication

        16.2.4. By Manufacturing Purpose

        16.2.5. By Route of Administration

        16.2.6. By Cell Type

        16.2.7. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Source

        16.3.3. By Indication

        16.3.4. By Manufacturing Purpose

        16.3.5. By Route of Administration

        16.3.6. By Cell Type

        16.3.7. By End User

    16.4. Key Takeaways

17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        17.2.1. By Country

            17.2.1.1. China

            17.2.1.2. Japan

            17.2.1.3. South Korea

        17.2.2. By Source

        17.2.3. By Indication

        17.2.4. By Manufacturing Purpose

        17.2.5. By Route of Administration

        17.2.6. By Cell Type

        17.2.7. By End User

    17.3. Market Attractiveness Analysis

        17.3.1. By Country

        17.3.2. By Source

        17.3.3. By Indication

        17.3.4. By Manufacturing Purpose

        17.3.5. By Route of Administration

        17.3.6. By Cell Type

        17.3.7. By End User

    17.4. Key Takeaways

18. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        18.2.1. By Country

            18.2.1.1. GCC Countries

            18.2.1.2. South Africa

            18.2.1.3. Israel

            18.2.1.4. Rest of MEA

        18.2.2. By Source

        18.2.3. By Indication

        18.2.4. By Manufacturing Purpose

        18.2.5. By Route of Administration

        18.2.6. By Cell Type

        18.2.7. By End User

    18.3. Market Attractiveness Analysis

        18.3.1. By Country

        18.3.2. By Source

        18.3.3. By Indication

        18.3.4. By Manufacturing Purpose

        18.3.5. By Route of Administration

        18.3.6. By Cell Type

        18.3.7. By End User

    18.4. Key Takeaways

19. Key Countries Market Analysis

    19.1. USA

        19.1.1. Pricing Analysis

        19.1.2. Market Share Analysis, 2022

            19.1.2.1. By Source

            19.1.2.2. By Indication

            19.1.2.3. By Manufacturing Purpose

            19.1.2.4. By Route of Administration

            19.1.2.5. By Cell Type

            19.1.2.6. By End User

    19.2. Canada

        19.2.1. Pricing Analysis

        19.2.2. Market Share Analysis, 2022

            19.2.2.1. By Source

            19.2.2.2. By Indication

            19.2.2.3. By Manufacturing Purpose

            19.2.2.4. By Route of Administration

            19.2.2.5. By Cell Type

            19.2.2.6. By End User

    19.3. Brazil

        19.3.1. Pricing Analysis

        19.3.2. Market Share Analysis, 2022

            19.3.2.1. By Source

            19.3.2.2. By Indication

            19.3.2.3. By Manufacturing Purpose

            19.3.2.4. By Route of Administration

            19.3.2.5. By Cell Type

            19.3.2.6. By End User

    19.4. Mexico

        19.4.1. Pricing Analysis

        19.4.2. Market Share Analysis, 2022

            19.4.2.1. By Source

            19.4.2.2. By Indication

            19.4.2.3. By Manufacturing Purpose

            19.4.2.4. By Route of Administration

            19.4.2.5. By Cell Type

            19.4.2.6. By End User

    19.5. Germany

        19.5.1. Pricing Analysis

        19.5.2. Market Share Analysis, 2022

            19.5.2.1. By Source

            19.5.2.2. By Indication

            19.5.2.3. By Manufacturing Purpose

            19.5.2.4. By Route of Administration

            19.5.2.5. By Cell Type

            19.5.2.6. By End User

    19.6. UK

        19.6.1. Pricing Analysis

        19.6.2. Market Share Analysis, 2022

            19.6.2.1. By Source

            19.6.2.2. By Indication

            19.6.2.3. By Manufacturing Purpose

            19.6.2.4. By Route of Administration

            19.6.2.5. By Cell Type

            19.6.2.6. By End User

    19.7. France

        19.7.1. Pricing Analysis

        19.7.2. Market Share Analysis, 2022

            19.7.2.1. By Source

            19.7.2.2. By Indication

            19.7.2.3. By Manufacturing Purpose

            19.7.2.4. By Route of Administration

            19.7.2.5. By Cell Type

            19.7.2.6. By End User

    19.8. Spain

        19.8.1. Pricing Analysis

        19.8.2. Market Share Analysis, 2022

            19.8.2.1. By Source

            19.8.2.2. By Indication

            19.8.2.3. By Manufacturing Purpose

            19.8.2.4. By Route of Administration

            19.8.2.5. By Cell Type

            19.8.2.6. By End User

    19.9. Italy

        19.9.1. Pricing Analysis

        19.9.2. Market Share Analysis, 2022

            19.9.2.1. By Source

            19.9.2.2. By Indication

            19.9.2.3. By Manufacturing Purpose

            19.9.2.4. By Route of Administration

            19.9.2.5. By Cell Type

            19.9.2.6. By End User

    19.10. Poland

        19.10.1. Pricing Analysis

        19.10.2. Market Share Analysis, 2022

            19.10.2.1. By Source

            19.10.2.2. By Indication

            19.10.2.3. By Manufacturing Purpose

            19.10.2.4. By Route of Administration

            19.10.2.5. By Cell Type

            19.10.2.6. By End User

    19.11. Russia

        19.11.1. Pricing Analysis

        19.11.2. Market Share Analysis, 2022

            19.11.2.1. By Source

            19.11.2.2. By Indication

            19.11.2.3. By Manufacturing Purpose

            19.11.2.4. By Route of Administration

            19.11.2.5. By Cell Type

            19.11.2.6. By End User

    19.12. Czech Republic

        19.12.1. Pricing Analysis

        19.12.2. Market Share Analysis, 2022

            19.12.2.1. By Source

            19.12.2.2. By Indication

            19.12.2.3. By Manufacturing Purpose

            19.12.2.4. By Route of Administration

            19.12.2.5. By Cell Type

            19.12.2.6. By End User

    19.13. Romania

        19.13.1. Pricing Analysis

        19.13.2. Market Share Analysis, 2022

            19.13.2.1. By Source

            19.13.2.2. By Indication

            19.13.2.3. By Manufacturing Purpose

            19.13.2.4. By Route of Administration

            19.13.2.5. By Cell Type

            19.13.2.6. By End User

    19.14. India

        19.14.1. Pricing Analysis

        19.14.2. Market Share Analysis, 2022

            19.14.2.1. By Source

            19.14.2.2. By Indication

            19.14.2.3. By Manufacturing Purpose

            19.14.2.4. By Route of Administration

            19.14.2.5. By Cell Type

            19.14.2.6. By End User

    19.15. Bangladesh

        19.15.1. Pricing Analysis

        19.15.2. Market Share Analysis, 2022

            19.15.2.1. By Source

            19.15.2.2. By Indication

            19.15.2.3. By Manufacturing Purpose

            19.15.2.4. By Route of Administration

            19.15.2.5. By Cell Type

            19.15.2.6. By End User

    19.16. Australia

        19.16.1. Pricing Analysis

        19.16.2. Market Share Analysis, 2022

            19.16.2.1. By Source

            19.16.2.2. By Indication

            19.16.2.3. By Manufacturing Purpose

            19.16.2.4. By Route of Administration

            19.16.2.5. By Cell Type

            19.16.2.6. By End User

    19.17. New Zealand

        19.17.1. Pricing Analysis

        19.17.2. Market Share Analysis, 2022

            19.17.2.1. By Source

            19.17.2.2. By Indication

            19.17.2.3. By Manufacturing Purpose

            19.17.2.4. By Route of Administration

            19.17.2.5. By Cell Type

            19.17.2.6. By End User

    19.18. China

        19.18.1. Pricing Analysis

        19.18.2. Market Share Analysis, 2022

            19.18.2.1. By Source

            19.18.2.2. By Indication

            19.18.2.3. By Manufacturing Purpose

            19.18.2.4. By Route of Administration

            19.18.2.5. By Cell Type

            19.18.2.6. By End User

    19.19. Japan

        19.19.1. Pricing Analysis

        19.19.2. Market Share Analysis, 2022

            19.19.2.1. By Source

            19.19.2.2. By Indication

            19.19.2.3. By Manufacturing Purpose

            19.19.2.4. By Route of Administration

            19.19.2.5. By Cell Type

            19.19.2.6. By End User

    19.20. South Korea

        19.20.1. Pricing Analysis

        19.20.2. Market Share Analysis, 2022

            19.20.2.1. By Source

            19.20.2.2. By Indication

            19.20.2.3. By Manufacturing Purpose

            19.20.2.4. By Route of Administration

            19.20.2.5. By Cell Type

            19.20.2.6. By End User

    19.21. GCC Countries

        19.21.1. Pricing Analysis

        19.21.2. Market Share Analysis, 2022

            19.21.2.1. By Source

            19.21.2.2. By Indication

            19.21.2.3. By Manufacturing Purpose

            19.21.2.4. By Route of Administration

            19.21.2.5. By Cell Type

            19.21.2.6. By End User

    19.22. South Africa

        19.22.1. Pricing Analysis

        19.22.2. Market Share Analysis, 2022

            19.22.2.1. By Source

            19.22.2.2. By Indication

            19.22.2.3. By Manufacturing Purpose

            19.22.2.4. By Route of Administration

            19.22.2.5. By Cell Type

            19.22.2.6. By End User

    19.23. Israel

        19.23.1. Pricing Analysis

        19.23.2. Market Share Analysis, 2022

            19.23.2.1. By Source

            19.23.2.2. By Indication

            19.23.2.3. By Manufacturing Purpose

            19.23.2.4. By Route of Administration

            19.23.2.5. By Cell Type

            19.23.2.6. By End User

20. Market Structure Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Market Share Analysis of Top Players

        20.3.1. By Regional

        20.3.2. By Source

        20.3.3. By Indication

        20.3.4. By Manufacturing Purpose

        20.3.5. By Route of Administration

        20.3.6. By Cell Type

        20.3.7. By End User

21. Competition Analysis

    21.1. Competition Deep Dive

        21.1.1. Merck KGaA

            21.1.1.1. Overview

            21.1.1.2. Product Portfolio

            21.1.1.3. Profitability by Market Segments

            21.1.1.4. Sales Footprint

            21.1.1.5. Strategy Overview

                21.1.1.5.1. Marketing Strategy

        21.1.2. Avantor, Inc.

            21.1.2.1. Overview

            21.1.2.2. Product Portfolio

            21.1.2.3. Profitability by Market Segments

            21.1.2.4. Sales Footprint

            21.1.2.5. Strategy Overview

                21.1.2.5.1. Marketing Strategy

        21.1.3. Cell Therapies Pty Ltd

            21.1.3.1. Overview

            21.1.3.2. Product Portfolio

            21.1.3.3. Profitability by Market Segments

            21.1.3.4. Sales Footprint

            21.1.3.5. Strategy Overview

                21.1.3.5.1. Marketing Strategy

        21.1.4. Thermo Fisher Scientific

            21.1.4.1. Overview

            21.1.4.2. Product Portfolio

            21.1.4.3. Profitability by Market Segments

            21.1.4.4. Sales Footprint

            21.1.4.5. Strategy Overview

                21.1.4.5.1. Marketing Strategy

        21.1.5. Charles River Laboratories

            21.1.5.1. Overview

            21.1.5.2. Product Portfolio

            21.1.5.3. Profitability by Market Segments

            21.1.5.4. Sales Footprint

            21.1.5.5. Strategy Overview

                21.1.5.5.1. Marketing Strategy

        21.1.6. Catalent, Inc

            21.1.6.1. Overview

            21.1.6.2. Product Portfolio

            21.1.6.3. Profitability by Market Segments

            21.1.6.4. Sales Footprint

            21.1.6.5. Strategy Overview

                21.1.6.5.1. Marketing Strategy

        21.1.7. Bio-Techne

            21.1.7.1. Overview

            21.1.7.2. Product Portfolio

            21.1.7.3. Profitability by Market Segments

            21.1.7.4. Sales Footprint

            21.1.7.5. Strategy Overview

                21.1.7.5.1. Marketing Strategy

        21.1.8. Cytiva

            21.1.8.1. Overview

            21.1.8.2. Product Portfolio

            21.1.8.3. Profitability by Market Segments

            21.1.8.4. Sales Footprint

            21.1.8.5. Strategy Overview

                21.1.8.5.1. Marketing Strategy

        21.1.9. Lonza

            21.1.9.1. Overview

            21.1.9.2. Product Portfolio

            21.1.9.3. Profitability by Market Segments

            21.1.9.4. Sales Footprint

            21.1.9.5. Strategy Overview

                21.1.9.5.1. Marketing Strategy

        21.1.10. The Discovery Labs

            21.1.10.1. Overview

            21.1.10.2. Product Portfolio

            21.1.10.3. Profitability by Market Segments

            21.1.10.4. Sales Footprint

            21.1.10.5. Strategy Overview

                21.1.10.5.1. Marketing Strategy

        21.1.11. BIOCENTRIQ

            21.1.11.1. Overview

            21.1.11.2. Product Portfolio

            21.1.11.3. Profitability by Market Segments

            21.1.11.4. Sales Footprint

            21.1.11.5. Strategy Overview

                21.1.11.5.1. Marketing Strategy

        21.1.12. FUJIFILM Diosynth Biotechnologies

            21.1.12.1. Overview

            21.1.12.2. Product Portfolio

            21.1.12.3. Profitability by Market Segments

            21.1.12.4. Sales Footprint

            21.1.12.5. Strategy Overview

                21.1.12.5.1. Marketing Strategy

        21.1.13. Novartis AG

            21.1.13.1. Overview

            21.1.13.2. Product Portfolio

            21.1.13.3. Profitability by Market Segments

            21.1.13.4. Sales Footprint

            21.1.13.5. Strategy Overview

                21.1.13.5.1. Marketing Strategy

        21.1.14. Bristol-Myers Squibb Company

            21.1.14.1. Overview

            21.1.14.2. Product Portfolio

            21.1.14.3. Profitability by Market Segments

            21.1.14.4. Sales Footprint

            21.1.14.5. Strategy Overview

                21.1.14.5.1. Marketing Strategy

        21.1.15. Gilead Sciences, Inc.

            21.1.15.1. Overview

            21.1.15.2. Product Portfolio

            21.1.15.3. Profitability by Market Segments

            21.1.15.4. Sales Footprint

            21.1.15.5. Strategy Overview

                21.1.15.5.1. Marketing Strategy

        21.1.16. WuXi AppTec.

            21.1.16.1. Overview

            21.1.16.2. Product Portfolio

            21.1.16.3. Profitability by Market Segments

            21.1.16.4. Sales Footprint

            21.1.16.5. Strategy Overview

                21.1.16.5.1. Marketing Strategy

        21.1.17. OXGENE

            21.1.17.1. Overview

            21.1.17.2. Product Portfolio

            21.1.17.3. Profitability by Market Segments

            21.1.17.4. Sales Footprint

            21.1.17.5. Strategy Overview

                21.1.17.5.1. Marketing Strategy

        21.1.18. Pharmaron

            21.1.18.1. Overview

            21.1.18.2. Product Portfolio

            21.1.18.3. Profitability by Market Segments

            21.1.18.4. Sales Footprint

            21.1.18.5. Strategy Overview

                21.1.18.5.1. Marketing Strategy

        21.1.19. Aldevron

            21.1.19.1. Overview

            21.1.19.2. Product Portfolio

            21.1.19.3. Profitability by Market Segments

            21.1.19.4. Sales Footprint

            21.1.19.5. Strategy Overview

                21.1.19.5.1. Marketing Strategy

        21.1.20. FLODESIGN SONICS

            21.1.20.1. Overview

            21.1.20.2. Product Portfolio

            21.1.20.3. Profitability by Market Segments

            21.1.20.4. Sales Footprint

            21.1.20.5. Strategy Overview

                21.1.20.5.1. Marketing Strategy

22. Assumptions & Acronyms Used

23. Research Methodology

Recommendations

Healthcare

Stem Cell Therapy Market

March 2022

REP-GB-1087

March 2024

315 pages

Healthcare

Cell Line Development Services Market

July 2017

REP-GB-4339

July 2023

324 pages

Healthcare

Blood Cancer Treatment Market

April 2016

REP-GB-1425

July 2023

339 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Cell Therapy Manufacturing Market